You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

rhuMAb-VEGF

Showing 1 - 25 of 1,314
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

Active, not recruiting
  • Recurrent Brain Neoplasm
  • Bevacizumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

Recruiting
  • Resectable Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +2 more
  • Houston, Texas
  • +1 more
Oct 12, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bevacizumab
  • +4 more
  • Phoenix, Arizona
  • +2 more
Jun 27, 2022

Advanced Cancer Trial in Houston (Dasatinib, Bevacizumab, Paclitaxel)

Completed
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Nov 21, 2022

Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Ovarian Cancer Trial in Houston (Paclitaxel, Bevacizumab, Lurbinectedin)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Nov 23, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +4 more
Aug 17, 2022

Liver Cancer Trial in Houston (Bevacizumab, Atezolizumab, Sofosbuvir)

Not yet recruiting
  • Liver Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 9, 2023

Glioma, Recurrent Glioma Trial in Shanghai (Hypofractionated Stereotactic Radiotherapy, Bevacizumab)

Active, not recruiting
  • Glioma
  • Recurrent Glioma
  • Shanghai, Shanghai, China
    CyberKnife Center, Department of Neurosurgery, Huashan Hospital
Nov 3, 2022

Liver Cancer Trial in Houston (Bevacizumab, Erlotinib)

Completed
Has Results
  • Liver Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Nov 3, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023

Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,

Not yet recruiting
  • Metastatic Colorectal Carcinoma
  • +3 more
  • Bevacizumab
  • +11 more
  • (no location specified)
May 9, 2023

Advanced Cancer Trial in Houston (Temsirolimus, Bevacizumab, Paclitaxel)

Active, not recruiting
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 11, 2022

Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)

Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Liver Metastases Trial in Houston (Leucovorin, 5-FLUOROURACIL, Oxaliplatin)

Recruiting
  • Liver Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Apr 26, 2022

Tumors, Ovarian Cancer, Breast Cancer Trial in Houston (ZN-c3, Bevacizumab, Pembrolizumab)

Not yet recruiting
  • Tumors
  • +4 more
  • Houston, Texas
    MD Anderson Cancer Center
Jun 20, 2022

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +6 more
  • Balstilimab
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Nov 17, 2022

Advanced Malignant Tumor, Castleman Disease, Digestive System Carcinoma Trial in Houston (biological, other, drug)

Active, not recruiting
  • Advanced Malignant Neoplasm
  • +38 more
  • Bevacizumab
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma Trial in Los Angeles, San Diego (biological, drug, other, genetic)

Active, not recruiting
  • Giant Cell Glioblastoma
  • +2 more
  • bevacizumab
  • +5 more
  • Los Angeles, California
  • +2 more
Feb 10, 2022

Peritoneal Malignant Mesothelioma Trial in United States (biological, drug, procedure)

Recruiting
  • Peritoneal Malignant Mesothelioma
  • Atezolizumab
  • +8 more
  • Phoenix, Arizona
  • +25 more
Feb 2, 2023